Back to search results

Study of [18F] Fluoroethyl-L-tyrosine PET/MRI for Pituitary Adenomas

This study is looking at a special type of scan called [18F] Fluoroethyl-L-tyrosine (FET) PET/MRI. This scan uses a small amount of a radioactive tracer ([18F]FET) to help doctors find small pituitary adenomas (non-cancerous growths on the pituitary gland) that might not show up on regular MRI scans. These adenomas can cause conditions like Cushing's Disease (CD), Acromegaly, or tumor hyperprolactinemia. The study aims to see how well FET-PET/MRI can detect these hidden tumors and if it helps doctors make better decisions about treatment, including surgery. You might be able to join if you are 18-75 years old, have one of these conditions, and your regular MRI didn't clearly show a tumor. The study will measure how accurately the FET-PET/MRI can find these tumors.

Study design
This is an interventional study with a planned enrollment of 5 participants. It is designed to evaluate the diagnostic role and clinical efficacy of FET-PET/MRI.
What's involved
You would undergo a PET/MR scan after receiving an intravenous (IV) administration of [18F]FET. The study measures the sensitivity of this scan at baseline.
Compensation
Not stated in the trial record.
Follow-up
Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07456878

Use of [18F] Fluoroethyl-L-tyrosine PET/MRI for Identifying Small Functional Pituitary Adenomas

Recruiting
PHASE1Ages 18–75InterventionalDiagnostic
Mayo Clinic
~5 participants
Updated 2026-03-09 on ClinicalTrials.gov
What's tested:FET-PET/MRI

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Sensitivity of [18F]FET-PET/MRI
Measured over Baseline

Conditions

Pituitary Adenoma

Explore related trials

Pituitary Neuroendocrine Tumor

NCT07456878

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Mayo Clinic

    Jacksonville, Floridastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Neetu Soni, MBBS, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

Julia Santos
[email protected]
904-953-3280
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients 18 to 75 years of age with biochemically proven CD, Acromegaly, or tumor hyperprolactinemia as per current Endocrinology guidelines.
Clinical DCE-MRI protocol that is negative or equivocal for identifiable tumor.
Patient willing to have surgery if lesion found, or already scheduled for surgery and lesion identification would be helpful.
Able to provide informed consent and be capable of completing the imaging protocols.
Female subjects of childbearing potential (women of childbearing potential \[WOCBP\]) must have a negative urine pregnancy test ≤48 hours prior to the 18F-FET injection.

Exclusion

Patients with contraindications to MRI or PET scans.
Patients with known allergies to contrast agents or other imaging-related materials.
Patients with severe medical conditions that preclude participation in the study (e.g. inability to lie supine for 30-60 minutes).
Patients with successful MRI localization of the adenoma.

What this trial measures

  • Sensitivity of [18F]FET-PET/MRIBaseline

    Percentage of cases where surgical findings and pathology are concordant with \[18F\]FET-PET/MRI imaging